Zylem Biosciences is a biotechnology company developing targeted medicines that modulate oxidative damage in human cells. Oxidative damage is implicated in many of the diseases that cause significant mortality and morbidity, including cancer and cardiovascular disease. It is also one of the prime causes of aging.
To meaningfully extend the healthy human lifespan, Zylem has created a long-term vision and roadmap that consists of three-stages:
Zylem’s science was developed over 15 years of research driven by Dr. Shad Thaxton’s lab at Northwestern University. Over $20M in funding—from NIH, Department of Defense, and the Howard Hughes Foundation—has been dedicated to the MRM platform technology.
Developing the MRM platform has enabled a deep understanding of how SR-B1 and other receptors are linked to cellular oxidative damage, lipid metabolism, and inflammation, and is critical to the progression of disease and aging.
The founding Zylem team consists of creative scientists, world-renowned experts, and experienced technology and biotechnology industry leaders. The patented technology exclusive to Zylem was born out of the work done by Dr. Thaxton and Dr. McMahon in the Thaxton Laboratory at Northwestern University. Dr. Gordon, a world-renowned expert in hematologic malignancies and longtime collaborator, played a key role in facilitating MRMs for aggressive lymphoma. Additionally, Zylem’s business leaders result from longstanding relationships with Dr. Thaxton. Mr. Bligh has successfully carried technology and biotechnology start-ups through IPO and FDA approval, respectively. Dr. Venkatesan has extensive experience in medicine, finance, and start-up biotechnology companies. Collectively, the Zylem team is a strategically assembled group of individuals with the expertise to translate Zylem’s first-in-class therapies to the clinic, and anti-aging compounds to commercial rollout.
PhD
PhD
MBA
MD